18 citations
,
January 1996 in “Gynecologic and obstetric investigation” The oral contraceptive alone is the preferred treatment for hirsutism, as adding the GnRH analog showed no significant benefit.
January 2023 in “Zenodo (CERN European Organization for Nuclear Research)” A new accurate and reliable method was developed to measure Spironolactone and Hydrochlorothiazide together in medicines.
November 2008 in “British Journal of Hospital Medicine” Non-drug methods effectively managed agitation in a patient with a heart device, leading to improved mental function.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” 5 citations
,
January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika” Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
January 2004 in “Headache” Divalproex sodium significantly improved headaches in two-thirds of patients.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
39 citations
,
January 2012 in “Acta dermato-venereologica” Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.
7 citations
,
September 2007 Valproate sustained-release is effective and generally safe for short-term treatment of new partial epilepsy.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
August 2008 in “European Neuropsychopharmacology” RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.
November 2001 in “The Journal of neuropsychiatry and clinical neurosciences/The journal of neuropsychiatry and clinical neurosciences” Divalproex sodium can unexpectedly cause agitation and hyperactivity in some patients.
21 citations
,
January 2023 in “Biomaterials Science” Microneedle patches with alpha-arbutin and resveratrol can effectively reduce skin pigmentation without irritation.
March 2025 in “SKIN The Journal of Cutaneous Medicine”
December 2010 in “Médecine des Maladies Métaboliques” The Accu-Chek FlexLink Plus and Accu-Chek LinkAssist Plus make insulin pump use safer, simpler, and more comfortable.
21 citations
,
September 2019 in “International Journal of Nanomedicine” RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.
February 2016 in “Journal of Allergy and Clinical Immunology” Consider DRIF and perform skin biopsies for persistent papular rashes.
May 2011 in “Value in Health” CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
1 citations
,
July 2015 in “The European research journal” Stopping aripiprazole can reverse its side effect of hair loss.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
39 citations
,
November 2015 in “Pediatric Nephrology” Rituximab leads to longer remission and fewer side effects than cyclophosphamide.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.